H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter“Fujirebio”) today announced that ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Industry experts weigh in on current trends, challenges, and the future of the cell and gene therapy CDMO market. Cell and gene therapies, which fall under the general classification of advanced ...

The U.S. Small Molecule Innovator API CDMO Market offers growth opportunities fueled by rising demand for HPAPIs across therapeutic areas like oncology, driven by FDA approvals and patent expirations.

【联化科技：始终坚持CDMO模式】财联社6月9日电，联化科技(002250.SZ)发布投资者关系活动记录表，公司K胺产品生产历史已超十年，并且公司专利期 ...

Indian pharma grapples headwinds of US pricing reform & Europe’s HTA-driven cost-effectiveness: Akash Kedia: Nandita Vijayasimha, Bengaluru Monday, June 9, 2025, 08:00 Hrs [IST] ...

National Resilience (“Resilience”), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today provided an update on its CDMO business strategy and ...